These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37867075)

  • 21. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 22. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropsychiatric symptoms with elexacaftor/tezacaftor/ivacaftor: What does this mean for children?
    Pham H; Vandeleur M; Ranganathan S
    Pediatr Pulmonol; 2024 Mar; 59(3):537-539. PubMed ID: 37991124
    [No Abstract]   [Full Text] [Related]  

  • 24. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
    FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
    Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
    Nichols D; Gifford A; Russell R; Odem-Davis K; Young J; Amaro-Galvez R; Billings J; Mukadam Z; Mayer-Hamblett N
    Ann Am Thorac Soc; 2024 Feb; 21(2):360-362. PubMed ID: 38019099
    [No Abstract]   [Full Text] [Related]  

  • 28. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease.
    Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL
    Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224
    [No Abstract]   [Full Text] [Related]  

  • 30. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
    Nathan N; Thouvenin G; Dubern B; Corvol H
    Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
    O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033
    [No Abstract]   [Full Text] [Related]  

  • 32. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.
    Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F
    Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

  • 35. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
    Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
    [No Abstract]   [Full Text] [Related]  

  • 36. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
    Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L
    Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822
    [No Abstract]   [Full Text] [Related]  

  • 37. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
    Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F
    J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
    Middleton PG; Taylor-Cousar JL
    Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
    [No Abstract]   [Full Text] [Related]  

  • 40. An acneiform eruption associated with elexacaftor/tezacaftor/ivacaftor treatment.
    Breneman A; Soliman YS; Gallitano SM
    Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.